News Overview

The initial public offering (IPO) encompasses a new equity issuance of up to Rs 600 crore along with an offer for sale (OFS) of up to Rs 425 crore.

The company said that net profit grew sequentially by 2.7% from Rs 736 crore in Q4FY23.

L&T Finance Holdings reported a tremendous 102.6% increase in consolidated net profit.

The approval enhances Lupin's Presence in the US market and reaffirms its commitment to providing accessible healthcare solutions.

Analysts of IIFL Capital Services forecast USD Revenue/EPS Cagr of 16%/15% over FY23-26. However, with the stock trading at 29x their FY25 P/E, they see the risk-reward as balanced. ADD.

The sale of approximately 16 million shares is estimated to generate approximately $501 million.

Robust performance expected on all key parameters.

Rupee opens at 82.72 paise compared to the previous close of 82.58 paise

Profitability likely to remain strong.

Company targets to reduce costs by Rs400/t over two years. It expects optimisation in Energy Costs, Logistics cost, and other expenses through Group synergies and efficiency capex.